WO1995026959A1 - Derive alkylenediamine - Google Patents
Derive alkylenediamine Download PDFInfo
- Publication number
- WO1995026959A1 WO1995026959A1 PCT/JP1995/000632 JP9500632W WO9526959A1 WO 1995026959 A1 WO1995026959 A1 WO 1995026959A1 JP 9500632 W JP9500632 W JP 9500632W WO 9526959 A1 WO9526959 A1 WO 9526959A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- alkyl
- general formula
- dioxide
- Prior art date
Links
- 125000005263 alkylenediamine group Chemical group 0.000 title claims abstract description 64
- -1 nitro, amino Chemical group 0.000 claims abstract description 274
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 116
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical group 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 336
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 37
- 125000005843 halogen group Chemical group 0.000 claims description 35
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 26
- 125000003277 amino group Chemical group 0.000 claims description 23
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000004104 aryloxy group Chemical group 0.000 claims description 15
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000005142 aryl oxy sulfonyl group Chemical group 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000001769 aryl amino group Chemical group 0.000 claims description 10
- 150000001721 carbon Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000000565 sulfonamide group Chemical group 0.000 claims description 9
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 32
- 206010013990 dysuria Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 4
- 230000036724 intravesical pressure Effects 0.000 abstract description 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 131
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 88
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 87
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 73
- 239000000243 solution Substances 0.000 description 57
- 239000000203 mixture Substances 0.000 description 52
- 239000002904 solvent Substances 0.000 description 48
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 30
- 238000002844 melting Methods 0.000 description 30
- 230000008018 melting Effects 0.000 description 30
- 239000013078 crystal Substances 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 21
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- XOAKQCOPHMCADA-UHFFFAOYSA-N 4,8-dioxatricyclo[5.1.0.03,5]octane Chemical compound C1C2OC2CC2OC12 XOAKQCOPHMCADA-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000010992 reflux Methods 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 14
- 239000005977 Ethylene Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- 239000012458 free base Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 230000008602 contraction Effects 0.000 description 11
- 239000001530 fumaric acid Substances 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- UOMTVKMKHZMFMQ-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide;hydrochloride Chemical compound Cl.O=S1(=O)CCNCC1 UOMTVKMKHZMFMQ-UHFFFAOYSA-N 0.000 description 10
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- LSVNPIZDHQPOSR-UHFFFAOYSA-N 1h-2,3-benzothiazine Chemical compound C1=CC=C2CSN=CC2=C1 LSVNPIZDHQPOSR-UHFFFAOYSA-N 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 8
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 7
- 125000004344 phenylpropyl group Chemical group 0.000 description 7
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 7
- 125000005505 thiomorpholino group Chemical group 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- UQMUIPXTUDIUJD-UHFFFAOYSA-N morpholin-3-ol Chemical compound OC1COCCN1 UQMUIPXTUDIUJD-UHFFFAOYSA-N 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 6
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229920001393 Crofelemer Polymers 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012456 homogeneous solution Substances 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- ZQAJMKNVQVOICB-UHFFFAOYSA-N 1,1-dioxo-2-propyl-1,2-benzothiazol-3-one Chemical compound C1=CC=C2S(=O)(=O)N(CCC)C(=O)C2=C1 ZQAJMKNVQVOICB-UHFFFAOYSA-N 0.000 description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- SDWVTCNYPZSVQY-UHFFFAOYSA-N (1-bromo-3-chloropropyl)benzene Chemical compound ClCCC(Br)C1=CC=CC=C1 SDWVTCNYPZSVQY-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OBGYOMBTRPHWPP-UHFFFAOYSA-N 1,1-dioxo-2,3-dihydro-1$l^{6},2-benzothiazin-4-one Chemical compound C1=CC=C2C(=O)CNS(=O)(=O)C2=C1 OBGYOMBTRPHWPP-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical group C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- NBWCGDRKSOXZNI-UHFFFAOYSA-N 2,3-dihydro-1h-benzo[de]isoquinoline Chemical group C1=CC(CNC2)=C3C2=CC=CC3=C1 NBWCGDRKSOXZNI-UHFFFAOYSA-N 0.000 description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 2
- PDGMIRNIVXVZGW-UHFFFAOYSA-N 3-propyl-1,2-benzothiazole 1,1-dioxide Chemical compound C(CC)C1=NS(C2=C1C=CC=C2)(=O)=O PDGMIRNIVXVZGW-UHFFFAOYSA-N 0.000 description 2
- RBSHGILPGKUDTP-UHFFFAOYSA-N 4-(3-chloro-3-phenylpropyl)morpholine Chemical compound C=1C=CC=CC=1C(Cl)CCN1CCOCC1 RBSHGILPGKUDTP-UHFFFAOYSA-N 0.000 description 2
- OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 description 2
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
- 206010027566 Micturition urgency Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000006178 methyl benzyl group Chemical group 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IWZJQGIFUBWZAE-UHFFFAOYSA-N 1-chloro-3-morpholin-4-ylpropan-2-ol Chemical compound ClCC(O)CN1CCOCC1 IWZJQGIFUBWZAE-UHFFFAOYSA-N 0.000 description 1
- NVJUHMXYKCUMQA-UHFFFAOYSA-N 1-ethoxypropane Chemical compound CCCOCC NVJUHMXYKCUMQA-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- DGVCYVIODIYGDQ-UHFFFAOYSA-N 2h-1,3-benzothiazine Chemical compound C1=CC=C2C=NCSC2=C1 DGVCYVIODIYGDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- VZGLVCFVUREVDP-UHFFFAOYSA-N 3-chlorobut-1-ene Chemical compound CC(Cl)C=C VZGLVCFVUREVDP-UHFFFAOYSA-N 0.000 description 1
- XZBXAYCCBFTQHH-UHFFFAOYSA-N 3-chloropropylbenzene Chemical compound ClCCCC1=CC=CC=C1 XZBXAYCCBFTQHH-UHFFFAOYSA-N 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- DCVGCQPXTOSWEA-UHFFFAOYSA-N 4-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]pyrazol-3-yl]methyl]-1-methylpiperazin-2-one Chemical compound CN1CCN(CC2=NN(CC(=O)N3CCC4=C(C3)N=NN4)C=C2C2=CN=C(NC3CC4=C(C3)C=CC=C4)N=C2)CC1=O DCVGCQPXTOSWEA-UHFFFAOYSA-N 0.000 description 1
- WUXPPVOAXYXHEG-UHFFFAOYSA-N 4-benzyl-1-(3-chloropropyl)piperidine Chemical compound C1CN(CCCCl)CCC1CC1=CC=CC=C1 WUXPPVOAXYXHEG-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- KBYPITRKIJKGMD-UHFFFAOYSA-N 4-phenoxypiperidine Chemical compound C1CNCCC1OC1=CC=CC=C1 KBYPITRKIJKGMD-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000021891 Micturition disease Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- HUWFMXJIHBKBCH-UHFFFAOYSA-N butan-2-one;dichloromethane Chemical compound ClCCl.CCC(C)=O HUWFMXJIHBKBCH-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006567 deketalization reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- QQKDTTWZXHEGAQ-UHFFFAOYSA-N propyl carbonochloridate Chemical compound CCCOC(Cl)=O QQKDTTWZXHEGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a novel alkylenediamine derivative which exhibits an effect of suppressing micturition contraction and is useful as a ⁇ component of a therapeutic agent for micturition disorder.
- R 1A and R 2A each independently represent an alkyl group, a halogen atom, a haloalkylyl group, a hydroxyl group, an alkoxyl group, an aryloxy group, an aralkyloxy group, a nitro group, an amino group, an alkylamino group, an aralkylamino group, and an arylamino.
- R 3 A and R 4A each independently represent a hydrogen atom Child, an alkyl group, Ararukiru group or Ariru group, or a R 3A and R 4A are bonded together with the nitrogen atom to which R 3A and R 4A are bonded, optionally further oxygen atom, contain a sulfur atom or a nitrogen atom Alkyl, aralkyl, phen
- a pharmacologically acceptable salt thereof can suppress micturition contraction that occurs when the bladder pressure is high, resulting in neurological dysuria, chronic prostatitis, chronic cystitis It can improve dysuria, urinary incontinence, urgency and residual urine in diseases or conditions such as neuropathic bladder and unstable bladder, and is useful as an active ingredient of a therapeutic agent for dysuria (See European Patent Application Publication No. 0579169A1 and Japanese Patent Application Laid-Open No. 6-80645).
- An object of the present invention is to provide a novel alkylenediamine derivative having an action of suppressing urinary contraction that occurs when the bladder pressure is high.
- the present invention provides a compound represented by the general formula (1):
- R 1 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a halogen atom, a haloalkyl group having 1 to 4 carbon atoms, a hydroxyl group, an alkoxyl group having 1 to 8 carbon atoms, and an aryloxy having 4 to 10 carbon atoms.
- R 2 is a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 9 carbon atoms, an alkoxyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms, or a halogen atom
- Aryl group with 5 to 11 carbon atoms An alkylsulfonyl group having 1 to 8 carbon atoms; an aralkyloxysulfonyl group having 1 to 4 carbon atoms; an aralkyloxysulfonyl group having 4 to 4 carbon atoms; 1 to 5 aryloxysulfonyl groups, sulfonamide groups and 1H-tetrazol-5-yl groups, which may have 1 to 5 identical or different substituents, carbon number 4 to An aryl group of I 0, an aralkyl group or an aromatic heterocyclic group having 5 to 5 carbon atoms;
- R 3 and R 4 are each independently a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) or a aralkyl group having 4 to 10 carbon atoms. It represents Ariru group, or, R 3 and R 4 and the force s bound, R 3 and R 4 force 'with binding nitrogen atom, further nitrogen atom as a ring-constituting atom, an oxygen atom or a sulfur atom Represents a heterocyclic group which may contain a child;
- k represents an integer of 1 to 4
- m and n independently represent an integer of 0 to 4 and m + n is 0 to 4
- p is 0, 1 or 2
- q is 0 or 1.
- w, x, y, and z each independently represent an integer of 0 to 2 and w + X + y + z is 1 or 2.
- alkylenediamine derivatives of the general formula (1) of the present invention preferred alkylenediamine derivatives are those represented by the general formula (2):
- the alkylene diamine derivative represented by the general formula (1) has a condensed heterocyclic ring containing a sulfur atom and a nitrogen atom at one end.
- the compound is completely different from the alkylenediamine derivative disclosed in Japanese Patent Application Laid-Open No. 0599169A1.
- the present invention also provides a compound of the general formula (I)
- R 1 is a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a halogen atom, a haloalkyl group having 1 to 4 carbon atoms, a hydroxyl group, an alkoxyl group having 1 to 8 carbon atoms, a carbon atom having 4 to 10 carbon atoms.
- Aryloxy group having 5 to 5 carbon atoms; aralkyloxy group having L 4 (alkyl group having 1 to 4 carbon atoms), nitro group, amino group, cyano group, alkylamino group having 1 to 8 carbon atoms, 5 to 1 carbon atoms 4 aralkylamino group having 1 to 4 carbon atoms in the alkylyl moiety, 4 to 4 carbon atoms; ararylamino group having 10 carbon atoms, aliphatic acylamino group having 1 to 8 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 9 carbon atoms, Aralkyloxycarbonyl group having 6 to 15 carbon atoms (1 to 4 carbon atoms in the alkyl moiety), araryloxycarbonyl group having 5 to 11 carbon atoms, dirubamoyl group, sulfo group, 1 carbon atom ⁇ 8 alkoxysulfonyl groups, 5 carbon atoms Alkaryloxysulfony
- R 2 is an alkyl group having 1 to 8 carbon atoms, a halogen atom, a haloalkyl group having 1 to 4 carbon atoms, a hydroxyl group, an alkoxyl group having 1 to 8 carbon atoms, an aryloxy group having 4 to 10 carbon atoms, and a carbon number.
- Aralkyloxy group of 5 to 14 (carbon number of alkyl moiety is 1 to 4) A nitro group, an amino group, a cyano group, an alkylamino group having 1 to 8 carbon atoms, an aralkylamino group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion), and an arylamino group having 4 to 10 carbon atoms A fatty acid having 1 to 8 carbon atoms B male acylamino group, a carboxyl group, an alkoxycarbonyl group having 2 to 9 carbon atoms, a carbon number of 6 to; an aralkyloxycarbonyl of L5 (carbon number of 1 to 4 in the alkyl portion) Group, aryloxycarbonyl group having 5 to 11 carbon atoms, sulfamoyl group, sulfo group, alkoxysulfonyl group having 1 to 8 carbon atoms, and carbon atom having 5 to 14 carbon atoms (alkyl
- R 3 and R 4 each represent ite, a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms of alkylyl) or a aralkyl group having 4 to 10 carbon atoms.
- Arukirire group having 1 to 5 carbon atoms, 5 to 4 carbon atoms (the alkyl moiety Aralkyl group, phenyl group, hydroxyl group, alkoxyl group having 1 to 8 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 9 carbon atoms, An aralkyloxycarbonyl group having a number of 1 to 4), an aryloxycarbonyl group having a carbon number of 5 to 11, an aliphatic acyl group having a carbon number of 1 to 8, and an aromatic acyl group having a carbon number of 5 to 11 And may have from 1 to 5 substituents selected from the group consisting of ):
- R 5 is a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, an aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkylyl moiety), a phenyl group, a 2-pyrimidinyl group, a carboxyl group Group, an alkoxycarbonyl group having 2 to 9 carbon atoms, an aralkyloxycarbonyl group having 6 to 15 carbon atoms (1 to 4 carbon atoms in the alkyl portion) and an aryloxycarbonyl group having 5 to 11 carbon atoms selected from the group consisting of the groups represented by represents a group), one 0-, -S-, one SO- or one S0 2 - represents a, t represents 0 or 1]
- n represents an integer of 0 to 4
- p and q independently represent an integer of 0 to 5
- p + q is 1 to 5
- X is 0, 1 Or 2 and y is 0 or 1]
- preferred alkylenediamine derivatives are those represented by the general formula (IV):
- saccharin-type alkylenediamine derivatives of the general formula (I) of the present invention are those represented by the general formula (V):
- the alkylenediamine derivative represented by the general formula (I) has a benzisothiazoline skeleton at one end, and is disclosed in the above-mentioned Japanese Patent Application Publication No. 0579169A1. It is a completely different compound from the min derivative.
- the halogen atom represented by R 1 is preferably fluorine, chlorine, bromine or the like, and particularly preferably chlorine.
- the alkyl group having 1 to 8 carbon atoms is preferably, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, octyl and the like.
- the haloalkyl group of 1 to 4 include, for example, trifluoro Methyl, chloromethyl, fluoromethyl and the like are preferable.
- alkoxy group having 1 to 8 carbon atoms for example, methoxy, ethoxy, propoxy and the like are preferable, and an aryloxy group having 4 to 10 carbon atoms (halogen atom, cyano group, alkyl Group, an alkoxy group, an amino group, an alkoxycarbonyl group or the like).), For example, phenoxy, parachlorophenoxy, etc. are preferred.
- aralkyloxy group having 1 to 4 carbon atoms include, for example, benzyloxy, pyridylmethyloxy, naphthylmethyloxy and tenyloxy, and the like.
- Preferred examples of the alkylamino group having 1 to 8 carbon atoms include methylamino.
- aralkylamino groups having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) (nuclear substituents such as halogen atoms, cyano groups, alkyl groups, alkoxyl groups, amino groups, and alkoxycarbonyl groups) are used.
- Examples thereof include benzylamino, (4-chlorophenyl) methylamino, etc., and an arylamino group having 4 to 10 carbon atoms (halogen atom, cyano group, alkyl group, alkoxyl group, amino group, (It may have a nuclear substituent such as an alkoxycarbonyl group.) Is, for example, phenylamino, parachlorophenylamino, etc. is preferred.
- a fatty acid male acrylamino group having 1 to 8 carbon atoms for example, acetylamino , Propionylamino and the like>'is preferable.
- alkoxycarbonyl group having 2 to 9 carbon atoms for example, Xycarbonyl, ethoxycarbonyl, propoxycarbonyl and the like are preferable.
- aralkyloxycarbonyl group having 6 to 15 carbon atoms (1 to 4 carbon atoms in the alkyl portion) include benzyloxycarbonyl, Preference is given to pyridylmethyloxycarbonyl, naphthylmethyloxycarbonyl, turoxycarbonyl and the like.
- aryloxycarbonyl group having 5 to 11 carbon atoms include phenoxycarbonyl, naphthyloxycarbonyl, and phenylcarboxycarbonyl.
- the alkoxysulfonyl group having 1 to 8 carbon atoms is, for example, methoxysulfonyl, ethoxysulfonyl or the like, and the carbon number is 5 to: 14 (the carbon number of the alkyl portion is 1 to 4).
- the aralkyloxysulfonyl group of) include benzyloxysulfonyl and naph Tylmethyloxysulfonyl, tenyloxysulfonyl and the like are preferred, and the aryloxysulfonyl group having 4 to 10 carbon atoms is, for example, pheno. Xisulfonyl, naphthyloxysulfonyl, chenyloxysulfonyl and the like are preferred.
- R 1 are a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms and an alkoxyl group having 1 to 8 carbon atoms.
- R 2 represents a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 9 carbon atoms, an alkoxyl group having 1 to 8 carbon atoms, or the same or It may have 1 to 5 different substituents, an aryl group having 4 to 10 carbon atoms, 5 to 5 carbon atoms; an aralkylyl group of I 4 (carbon number of 1 to 4 in the alkyl portion) or an aromatic complex ⁇ represents a group.
- alkylene group having 1 to 8 carbon atoms represented by R 2 for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, octyl and the like are preferable, and alkenyl having 2 to 9 carbon atoms
- the group include aryl, 1-propenyl, 2-methyl-2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-3-butenyl , 3-Methyl-2-butenyl, 4-pentenyl, 4-methyl-41-pentenyl, 4-methyl-3-pentenyl, 5-hexenyl, 5-methyl-5-hexenyl, 5-methyl-4-hexenyl, 6- Heptenyl, 6-methyl-6-heptenyl, 6-methyl-5-butenyl, 7-octenyl, 7
- aralkyl group having the number of 5 to 14 alkyl group having 1 to 4 carbon atoms
- benzyl, naphthylmethyl, and the like are preferable.
- aromatic heterocyclic group a furan ring, a thiophene ring, a pyridine ring, and a quinoline
- the indole ring is preferred.
- the halogen atom is preferably fluorine, chlorine, bromine or the like
- the alkyl group having 1 to 8 carbon atoms is preferably For example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, octyl, etc.
- haloalkyl groups having 1 to 4 carbon atoms include, for example, trifluoromethyl, chloromethyl, Fluoromethyl and the like are preferable, and an alkoxyl group having 1 to 8 carbon atoms
- methoxy, ethoxy, propoxy, etc. are preferred, and aryloxy groups having 4 to 10 carbon atoms (halogen atoms, cyano groups, alkyl groups, alkoxyl groups, amino substituents such as amino groups, alkoxycarbonyl groups, etc.) ),
- phenoxy, parachlorophenoxy, etc. are preferable.
- Examples of the aralkyloxy group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) include, for example, benzyloxy, Preferred are benzyloxy, pyridylmethyloxy, naphthylmethyloxy, tenyloxy and the like.
- Examples of the alkylamino group having 1 to 8 carbon atoms include, for example, methylamino, dimethylamino, ethylamino, propylamino, isobutylamino, etc.
- Aralkyl of 14 (C 1-4 of alkyl part)
- amino group which may have a nuclear substituent such as a halogen atom, a cyano group, an alkyl group, an alkoxyl group, an amino group or an alkoxycarbonyl group
- examples of the amino group include, for example, benzylamino, (4-chlorophenyl) methylamino and the like.
- the arylamino group having 4 to 10 carbon atoms (which may have a nuclear substituent such as a halogen atom, a cyano group, an alkyl group, an alkoxyl group, an amino group, an alkoxycarbonyl group) is, for example, phenylamino And parachlorophenylamino, etc.
- a fatty acid aminosilamino group having 1 to 8 carbon atoms are, for example, acetylamino, butylpyonyylamino, etc.
- an alkoxycarbonyl group having 2 to 9 carbon atoms is, for example, Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl Power 5
- the aryloxycarbonyl group having 5 to 11 carbon atoms includes, for example, phenoxycarbonyl, pyridylmethyloxycarbonyl, naphthylmethyloxycarbonyl, tenyloxycarbonyl and
- the alkoxysulfonyl group having 1 to 8 carbon atoms is, for example, methoxysulfonyl, ethoxysulfonyl or the like, and an aralkyl having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion).
- oxysulfonyl group examples include benzyloxysulfonyl, naphthylmethyl Kishisuruhoniru, tennis Ruo carboxymethyl sulfonyl are preferable, as the ⁇ reel O carboxymethyl sulfonyl group 4-1 0 carbon atoms, for example, phenoxyethanol sulfonyl, naphthoquinone Preference is given to tyloxysulfonyl, cheloxysulfonyl and the like.
- R 2 is particularly preferably a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxyl group having 1 to 8 carbon atoms, a hydroxyl group, a phenyl group having no substituent, a furyl group, a phenyl group or a pyridyl group, Or a phenyl group having a halogen atom, an alkylyl group having 1 to 8 carbon atoms, or an alkoxyl group having 1 to 8 carbon atoms as a substituent.
- the alkyl group having 1 to 8 carbon atoms includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, etc.
- the aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) is, for example, benzyl, phenylethyl, phenylpropyl, etc.
- the aralkyl group having 4 to 10 carbon atoms is, for example, Phenyl, pyridyl, naphthyl and the like: ⁇ preferred.
- R 3 and R 4 and the force s bound represent together with R 3 and R 4 force s bonded to the nitrogen atom, further nitrogen atom as ⁇ constituting atom, an oxygen atom or heterocyclic ⁇ but it may also contain a sulfur atom
- a preferred group is represented by the following general formula (4):
- R 5 is a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, an aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion), a phenyl group, a 2-pyrimidinyl group, a carboxyl group
- morpholino for example, morpholino, piperidino, homomorpholino, 1-pyrrolidinyl, thiomorpholino, 1-pirazinyl, perhydroazepine-11-yl , S-Salt xythiomorpholino, S, S-dioxythiomorpholino and the like are preferred.
- examples of the alkylyl group having 1 to 8 carbon atoms include methyl and ethyl. , Propyl, isopropyl, butyl, isobutyl, etc. are preferable.
- the aralkyl group having 5 to 14 carbon atoms for example, benzyl, phenylethyl, phenylpropyl, etc. are preferable.
- the alkoxycarbonyl group having 2 to 9 is preferably, for example, methoxycarbonyl, ethoxycarbonyl, methoxycarbonyl, etc., and preferably has 6 to 15 carbon atoms (aralkylo having 1 to 4 carbon atoms in the alkyl portion).
- Examples of the xycarbonyl group include, for example, benzyloxycarbonyl, pyridylmethyloxycarbonyl, naphthylmethyloxycarbonyl, and phenyloxy Rubo sulfonyl like mosquitoes S
- the ⁇ reel O carboxymethyl carbonylation Le group having a carbon number of 5 to 1 1 phenoxyethanol carbonyl, naphthyl O alkoxycarbonyl, Cheniruo butoxycarbonyl, etc. are preferred.
- the 5- to 7-membered heterocyclic group represented by the above general formula (4), 1,2,3,4-tetrahydroisoquinoline group, or 2,3-dihydro-1H-benz [de] isoquinoline group is An aryl group having 4 to 10 carbon atoms as a substituent (substituted by a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxyl group having 1 to 5 carbon atoms, or an aliphatic acyl group having 1 to 5 carbon atoms) Or an alkyl group having 1 to 8 carbon atoms, a phenyl group, a hydroxyl group, or an aryl group having 4 to 10 carbon atoms as a substituent (halogen atom, 1 to 5 carbon atoms) An alkyl group, an alkoxyl group having 1 to 5 carbon atoms or an aliphatic acyl group having 1 to 5 carbon atoms), an alkoxyl group having 1 to 8 carbon atom
- the alkyl group having 1 to 5 carbon atoms is preferably, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like, and may have 4 to 10 carbon atoms which may have a substituent.
- Examples of the alkylene group having 1 to 8 carbon atoms which may have one or two aryl groups include, for example, benzyl, phenylethyl, phenylpropyl, diphenylmethyl, cyclobenzyl, methylbenzyl, methoxybenzyl, Acetyl pendyl, phenylmethyl, etc.
- the group include, for example, methoxy, ethoxy, propoxy, benzyloxy, diphenylmethyloxy, phenylethyloxy, and chlorobenzene.
- Methylbenzyloxy, methoxybenzyloxy, acetylbenzyloxy, 2- phenylmethyloxy, naphthylmethyloxy, 2-pyridylmethyloxy, naphthylmethyloxy, dichlorobenzyloxy, dichloro Mouth phenyl) methyloxy and the like are preferable.
- aryloxy group having 4 to 10 carbon atoms examples include phenoxy, chlorophenoxy, 3-phenyloxy, methoxyphenoxy, methylphenoxy, acetylphenoxy, dichlorophenoxy, nachloro Phthyloxy, black naphthyloxy, 4-pyridyloxy isothermic s is preferable, and the aralkylthio group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) includes, for example, benzylthio, phenylethylthio, and black benzylthio.
- the group examples include, for example, phenylthio, 3-phenylthio, methoxyphenylthio, methylphenylthio, acetylphenylthio, dichloromethylphenyl, naphthylthio, chloronaphthylthio, and 4-pyridylthio.
- the alkoxycarbonyl group having 2 to 9 carbon atoms is, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc., and is preferably an aralkyloxy having 6 to 15 carbon atoms (1 to 4 carbon atoms in the alkyl portion).
- the carbonyl group for example, benzyloxycarbonyl, pyridylmethyloxycarbonyl, naphthylmethyloxycarbonyl, tenyloxycarbonyl and the like are preferable.
- the aryloxycarbonyl group having 5 to 11 carbon atoms include: Phenoxycarbonyl, naphthyloxycarbonyl, chenyloxycarbonyl and the like are preferable.
- the aliphatic acetyl group having 1 to 8 carbon atoms for example, formyl, acetyl, propionyl and the like are preferable, and 5 to 11 carbon atoms are preferable.
- the aromatic acyl group include benzoyl and phthaloyl. There. When two JiLh substituents are bonded, these substituents may be the same or different from each other.
- heterocyclic group represented by the general formula (4) Particularly preferred as the 5- to 7-membered heterocyclic group represented by the general formula (4) are: morpholino, piperidino, homomorpholino, 1-pyrrolidinyl, thiomorpholino, 1-piperazinyl, perhydroazepine , S-oxythiomorpholino, S, S-dioxythiomorpholino and the like.
- These heterocyclic groups may have no substituent, or may have one or two carbon atoms having 1 to 8 carbon atoms such as an alkyl group or a phenyl group at a carbon atom or a nitrogen atom.
- It may have a substituent such as an alkyl group having 1 to 8 groups, a phenyl group, a phenyl group, a sacyl group having 1 to 8 carbon atoms, a carpamoyl group and a 2-pyrimidinyl group.
- a substituent such as an alkyl group having 1 to 8 groups, a phenyl group, a phenyl group, a sacyl group having 1 to 8 carbon atoms, a carpamoyl group and a 2-pyrimidinyl group.
- k is preferably 1 or 2, and particularly preferably 1.
- m is preferably 0, and n is preferably 1, 2 or 3.
- q 0, there are two hydrogen atoms.
- the alkylenediamine derivative represented by the general formula (1) can be synthesized using a reaction known in the technical field of organic compounds.
- alkylene diamine derivative of the general formula (2) is represented by the general formula (6):
- R 2 , R 3 , m and n are as defined in the general formula (1), and Q represents a leaving group such as a halogen atom, a tosyloxy group or a mesityloxy group
- the ketallic compound represented by the general formula (6) and the compound represented by the general formula (7) are mixed with acetone, dimethylformamide, methylethyl ketone, isobutyl methyl ketone, isopropyl alcohol, ethanol, Room temperature to reflux in an organic solvent such as dimethoxetane in the presence of a base such as potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium hydride, metal sodium, sodium methoxide, sodium hydroxide, etc.
- a base such as potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium hydride, metal sodium, sodium methoxide, sodium hydroxide, etc.
- the ethylene ketal compound was diluted with a dilute hydrochloric acid, a dilute hydrochloric acid / methanol mixture, a dilute hydrochloric acid / tetrahydrofuran mixture, a dilute hydrochloric acid / ethanol mixture, a sulfuric acid / acetone mixture, a paratoluenesulfonic acid / acetone mixture, 8
- the alkylenediamine derivative represented by the general formula (2) is represented by the general formula (8):
- the ethylene ketal compound can be produced by reacting the compound with the compound represented by the formula (1) and deketalizing the resulting ethylene ketal compound.
- an ethylene ketal compound corresponding to the compound represented by the general formula (2) is obtained. Then, the ethylene ketal compound is deketalized by the above-mentioned method to synthesize an alkylenediamine derivative represented by the general formula (2). In this reaction, it is preferable to use 1 to 2 mol of the compound of the general formula (9) per 1 mol of the compound of the general formula (8).
- a compound similar to the compound of the general formula (2), wherein P is 0 or 1 or q is 0 in the general formula (1), can also be synthesized by the same method as described above.
- the compound represented by the general formula (10) and the compound represented by the general formula (7) are mixed with acetone, dimethylformamide, methylethylketone, isobutylmethylketone, isopropyl alcohol, Room temperature to reflux temperature in an organic solvent such as ethanol or dimethoxyethane in the presence of a base such as potassium carbonate, sodium carbonate, cesium carbonate, baking soda, sodium hydride, metal sodium, sodium ethoxide, sodium hydroxide, etc. Then, the reaction is carried out for 1 to 50 hours to synthesize a compound represented by the general formula (3). In this reaction, 1 to 2 mol of the compound represented by the general formula (7) and 2 to 8 mol of the above base are used per 1 mol of the compound represented by the general formula (10). That force 'preferred.
- the alkylenediamine derivative represented by the general formula (3) is represented by the general formula (11):
- the compound represented by the general formula (11) and the compound represented by the general formula (9) are usually used without solvent in the range of 50 to I50.
- the compound represented by the general formula (3) is synthesized by reacting at a temperature of C for 1 to 20 hours. If necessary, an inert solvent may be used in this reaction.
- the production conditions for synthesizing the alkylene diamine derivative represented by the general formula (13) and the alkylene diamine derivative represented by the general formula (15) are represented by the compound represented by the general formula (10) and the compound represented by the general formula (7).
- the conditions are the same as those for producing the alkylenediamine derivative represented by the general formula (3) from the compound to be prepared.
- a compound similar to the compound represented by the general formula (13) or the general formula (15), in which the force ⁇ or q in which P is 0 or 1 in the general formula (1) is 0, can be obtained in the same manner as described above. Can be synthesized. —The alkylenediamine derivative represented by the general formula (1) can be converted into a pharmacologically acceptable salt.
- the ⁇ S chemically acceptable salt of the alkylenediamine derivative represented by the general formula (1) includes an inorganic acid (eg, hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid) or an organic acid (eg, fumaric acid) Acetic acid, propionic acid, citric acid, tartaric acid, maleic acid, malic acid, oxalic acid, methanesulfonic acid, paratoluenesulfonic acid).
- an inorganic acid eg, hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid
- organic acid eg, fumaric acid
- Tables 1 and 2 show typical examples of the alkylenediamine derivative of the present invention.
- Table 1 shows the compound represented by the general formula (2) and the compound represented by the general formula (3), and the symbols described in Table 1 indicate the symbols in the general formulas (2) and (3). Symbol.
- Table 2 shows the compounds represented by the general formula (13) and the general formula (
- H H 4 Diphenylmethyloxybiveridino 10 2 —Black mouth H 4 Diphenylmethyloxybiperidino 10 2 —Methyl H 4 diphenylmethyi ⁇ (Rethoxybiberidino 10 2
- the halogen atom represented by R 1 is preferably fluorine, chlorine, bromine or the like, particularly preferably chlorine.
- the alkyl group having 1 to 8 carbon atoms e.g., methyl, Echiru, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, Okuchiru like are preferable.
- the haloalkyl group having 1 to 4 carbon atoms for example, trifluoromethyl, chloromethyl, fluoromethyl and the like are preferable
- the alkoxyl group having 1 to 8 carbon atoms for example, methoxy, ethoxy, propoxy, etc.
- Examples of the aryloxy group having 4 to 10 carbon atoms include, for example, phenoxy And parachlorophenoxy, etc., and are preferably aralkyl having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion).
- oxy group for example, benzyloxy, pyridylmethyloxy, naphthylmethyloxy, and tenyloxy are preferred.
- alkylamino group having 1 to 8 carbon atoms for example, methylamino, dimethylamino, ethylamino, propylamino And aralkylamino groups having 5 to 14 carbon atoms (alkyl groups having 1 to 4 carbon atoms) (halogen atom, cyano group, alkyl group, alkoxyl group, amino group, alkoxycarbonyl ⁇ ).
- Examples of the (optionally substituted) group include benzylamino, (4-chlorophenyl) methylamino and the like, and an arylamino group having 4 to 10 carbon atoms (halogen atom, cyano group, alkyl group, alkoxyl group, ⁇ Has a nuclear substituent such as an amino group or an alkoxyl Phenylamino, parachlorophenylamino, etc. are preferred, and the C1-C8 fatty maleamino group is, for example, acetylamino, propionylamino, etc.
- the alkoxycarbonyl group of the number 2 to 9 for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and the like are preferable, and the carbon number 6 to: an aralkyl carbonyl group of L5 (the carbon number of the alkyl portion is 1 to 4)
- the carbon number 6 for example, preferred are benzyloxycarbonyl, pyridylmethyloxycarbonyl, naphthylmethyloxycarbonyl, turoxyl propyl and the like.
- the alkoxysulfonyl group having 1 to 8 carbon atoms for example, main Tokishisuruhoniru, E WINCH Kishisuruhoniru like mosquitoes s
- the alkoxysulfonyl group having 1 to 8 carbon atoms for example, main Tokishisuruhoniru, E WINCH Kishisuruhoniru like mosquitoes s
- the alkoxysulfonyl group having 1 to 8 carbon atoms for example, main Tokishisuruhoniru, E WINCH Kishisuruhoniru like mosquitoes s
- the aralkyloxysulfonyl group include, for example, benzyloxysulfonyl, naphthylmethyloxysulfonyl, and turoxysulfonyl, and the like.
- the aryloxysulfonyl group having 4 to 10 carbon atoms include: Phenoxysul
- R 1 is particularly preferably a hydrogen atom, a halogen atom, or an alkoxyl group having 1 to 8 carbon atoms.
- R 2 represents a phenyl group, a naphthyl group or an aromatic heterocyclic group which may have 1 to 5 identical or different substituents, and preferred examples thereof are the same or different Examples thereof include a phenyl group, a naphthyl group, a furan group, a thiophene ring, a pyridine group, a quinoline ring and an indole ring which may have 1 to 5 substituents.
- a halogen atom is preferably fluorine, chlorine, bromine, etc.
- an alkyl group having 1 to 8 carbon atoms is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, Hexyl, heptyl, octyl and the like are preferable.
- the haloalkyl group having 1 to 4 carbon atoms include, for example, trifluoromethyl, chloromethyl, and fluoromethyl.
- the alkoxy group having 1 to 8 carbon atoms include methoxy, Ethoxy, propoxy and the like are preferable, and an aryloxy group having 4 to 10 carbon atoms (which may have a nuclear substituent such as a halogen atom, a cyano group, an alkyl group, an alkoxyl group, an amino group or an alkoxycarbonyl group)
- a nuclear substituent such as a halogen atom
- aralkyloxy group having 5 to 14 (C 1 to C 4 in the alkyl portion)
- benzyloxy, benzyloxy, pyridylmethyloxy, naphthylmethyloxy, turoxy and the like are preferable, and as the alkylamino group having 1 to 8 carbon atoms.
- Is preferably, for example, methylamino, dimethylamino, ethylamino, propylamino, isobutylamino, etc., and an aralkylamino group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) (halogen atom, cyano group, alkyl group, alkoxyl group) , An amino group, an alkoxycarbonyl group, etc.)
- benzylamino, (4-chlorophenyl) methylamino and the like are preferable, and arylamino groups having 4 to 10 carbon atoms (halogen atom, cyano group, alkyl group, alkoxyl group, amino group, alkoxy group) (It may have a nucleus substituent such as a carbonyl group.) Examples thereof include phenylano and parachlorophenylamino, and the like.
- Preferred examples thereof include acetylamino groups having 1 to 8 carbon atoms. Lamino, propionylamino and the like are preferable.
- the alkoxycarbonyl group having 2 to 9 carbon atoms for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and the like are preferable, and 6 to 15 carbon atoms (of the alkyl moiety)
- the aralkyloxycarbonyl group having 1 to 4 carbon atoms include benzyloxycarbonyl, Preferred are zirmethyloxycarbonyl, naphthylmethyloxycarbonyl, tenyloxycarbonyl and the like.
- aryloxycarbonyl group having 5 to 11 carbon atoms examples include phenoxycarbonyl, pyridylmethyloxycarbonyl, Preferred are naphthylmethyloxycarbonyl, tenyloxycarbonyl and the like, and as the alkoxysulfonyl group having 1 to 8 carbon atoms, for example, methoxysulfonyl, ethoxysulfonyl and the like are preferable, and carbon atoms of 5 to 14 (of the alkylyl moiety)
- the aralkyloxysulfonyl group having 1 to 4 carbon atoms is preferably, for example, benzyloxysulfonyl, naphthylmethyloxysulfonyl, tenyloxysulfonyl and the like, and preferably an aralkyloxy having 4 to 10 carbon atoms.
- the sulfonyl group examples include phenoxysulfonyl and naphthyl Okishisuruhoniru, Choi two Ruo carboxymethyl sulfonyl, and the like are preferable.
- the group represented by R 2 is preferably a phenyl group or a phenyl group which may have 1 to 5 identical or different substituents, and more preferably a phenyl group or a substituent having no substituent.
- the alkylyl group having 1 to 8 carbon atoms is preferably, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, etc.
- Preferred examples of the benzyl group include benzyl, phenylethyl and phenylpropyl
- preferred examples of the aryl group having 4 to 10 carbon atoms include phenyl, pyridyl and naphthyl.
- R 3 and to force engagement the 5-7 membered heterocyclic ⁇ represented by R 3 and R 4 force s bonded to the nitrogen atom formula you formed with ([pi), for example, morpholino, piperidino, homo Preferred are morpholino, 1-pyrrolidinyl, thiomorpholino, 1-piperazinyl, 1-perhydroazepyr, S-hydroxythiomorpholino, S, S-dioxythiomorpholino and the like.
- examples of the alkyl group having 1 to 8 carbon atoms include methyl, ethyl, propyl, isopropyl, Preferred are butyl, isobutyl and the like.
- examples of the aralkyl group having 5 to 14 carbon atoms (1 to 4 carbon atoms in the alkyl portion) are, for example, preferably benzyl, phenylethyl, phenylpropyl and the like, and 2 to 9 carbon atoms.
- examples of the alkoxycarbonyl group include, for example, methoxycarbonyl, ethoxycarbonyl, propoxyl, and the like.
- C 6 to L 5 (C 1 to C 4 alkylalkyloxycarbonyl groups).
- alkyl groups having 1 to 5 carbon atoms include, for example, methyl, ethyl, propyl, isopropyl, butyl Aralkyl groups having 5 to 4 carbon atoms (alkyl groups having 1 to 4 carbon atoms), such as benzyl, phenylethyl and phenylpropyl, are preferred; and alkoxyl groups having 1 to 5 carbon atoms are preferred. For example, methoxy, ethoxy, propoxy, and the like are preferable.
- alkoxycarbonyl group having 2 to 6 carbon atoms for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and the like are preferable, and 6 to 15 carbon atoms (alkyl moiety).
- examples of the aralkyloxycarbonyl group having 1 to 4 carbon atoms include benzyloxycarbonyl and pyridyl Methyloxycarbonyl, naphthylmethyloxycarbonyl, and turoxycarbonyl are preferred.
- aryloxycarbonyl group having 5 to 11 carbon atoms phenoxycarbonyl, naphthyloxycarbonyl, chenyloxycarbonyl and the like are preferred.
- a fatty acid male group having 1 to 8 carbon atoms for example, formyl, acetyl, propionyl and the like are preferable, and as an aromatic acyl group having 5 to 11 carbon atoms, for example, benzoyl, phthaloyl, etc. preferable.
- substituents may be the same or different from each other.
- Particularly preferred as the 5- to 7-membered heterocyclic group of the general formula (H) are those having no substituent or having an alkyl group having 1 to 8 carbon atoms or a phenyl group at a carbon atom and Z or a nitrogen atom.
- m is preferably 1 or 2, and more preferably 1 and s. n is preferably 0, 1 or 2, and particularly preferably 0. P is preferably 0, force s, and q is 1, 2 or 3, force 3 .
- the alkylenediamine derivative in which X is 2 and y is 1 is an alkylenediamine derivative of the general formula (W), and in the general formula (I), X is 1 Wherein y is 1 is an alkylenediamine derivative represented by the general formula (V).
- an alkylenediamine derivative wherein X is 2 and y is 0 is represented by the general formula (VI )).
- alkylene diamine derivative represented by the general formula (I) is represented by the general formula (VI):
- R 2 , R 3 , R 4 , n, p and q are as defined in the general formula (I), and Q is a leaving group such as a halogen atom, a tosyloxy group or a mesityloxy group. Represents)
- a compound of the general formula ( ⁇ ) and a compound of the general formula (grape) are mixed in an organic solvent such as acetone, methylethylketone, isobutylmethylketone, and dimethylformamide with potassium carbonate, sodium carbonate,
- the compound of general formula (I) is synthesized by reacting at room temperature to reflux temperature for 1 to 50 hours in the presence of a carbonate such as cesium carbonate, etc.
- the compound of general formula (VI) is synthesized. It is preferable to use 1 to 2 mol of the compound of the general formula (VI) and 2 to 8 mol of the carbonate for 1 mol of the compound of the general formula (VI). It is preferable to use the compound in the form of S.
- the alkylene diamine derivative represented by the general formula (I) is represented by the following general formula (IX):
- R 1 , R 2 , m, n, P, q, x and y are as defined in the general formula (I), and Q is a halogen atom, a tosyloxy group or a mesityloxy group. Represents a leaving group
- the compound of the general formula (I) is reacted with the compound of the general formula (K) and the compound of the general formula (X) for 1 to 20 hours at a temperature of 50 to L5 CTC, usually without solvent. Synthesize the compound. If necessary, an inert solvent may be used in this reaction.
- the alkylenediamine derivative represented by the general formula (I) can be converted into a pharmacologically acceptable salt.
- the pharmacologically acceptable salt of the alkylenediamine derivative of the general formula (I) includes an inorganic acid (eg, hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid) or an organic acid (eg, fumaric acid, Acid addition salts of acetic acid, propionic acid, citric acid, tartaric acid, maleic acid, malic acid, oxalic acid, methanesulfonic acid, and paratoluenesulfonic acid.
- an inorganic acid eg, hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid
- organic acid eg, fumaric acid, Acid addition salts of acetic acid, propionic acid, citric acid, tartaric acid, maleic acid, malic acid, oxalic acid, methanesulfonic acid, and paratoluenesulfonic acid.
- alkylene diamine derivative represented by the general formula (I) of the present invention are shown in Table 3 using the symbols in the general formula (I). 95/26959
- Test method Four The effect of the compound of the present invention on urinary contraction of the bladder was evaluated by the following test method. Test method
- Wistar male rats were fixed in a dorsal position under urethane anesthesia (1. S g / kg, S. C.). An airway was secured by inserting a tracheal forcenula, and a midline incision was made in the lower abdomen. The bladder was exposed, a small hole was made in the top of the bladder, and urine was excreted. Then, a polyethylene-made neuron with an outer diameter of about lmm was inserted into the bladder. The urethra and ureter were tied, and the bladder was closed.
- saline was infused into the bladder of the rat at a rate of 0.05 mLZ to induce periodic micturition contraction, and the pressure in the bladder was changed via a pressure transuser. Measured and recorded on a pen writing recorder. Drugs were dissolved in saline and administered via femoral vein into the femoral vein.
- the effect of suppressing micturition contraction was evaluated by measuring the time during which rhythmic bladder contraction was stopped after drug administration (contraction stop time).
- Table 4 shows the contraction arrest time measured for each of the compounds obtained in the examples as drugs.
- Example 20 [A] 120 Jil ⁇ 12 69.7 Example 20 [B] 140 6 20.4 Example 20 [C] 180 6 26.0 Example 24 [A] 62 12 8 5.6 Example Example 24 [B] 32 6 2 8.5 Example 24 [C] 167 6 2 0.7 Example 21 1 ⁇ O Lh 10 17.0 Example 26 37 4 27.3 Example 10 3 8 2 14.5 Example i 1 37 8 4 3.9 Example 12 8 22.5 Example 1 1 3 2.8 Example 14 17 8 3 12.7 Example 15 23 8 3 4.7 Example 3 8 2 2 Example 2 to — 8 2 16 Example 13 8 2 18 Example 16 8 3 —
- Example 32 8 3 6
- Example 34 8 2 3
- Example K 48 5 4 10.7
- Table 4 shows LD S0 (mg / kg) calculated by the Probit method for the toxicity of the compound of the present invention.
- the alkylenediamine derivative of the present invention or a pharmacologically acceptable salt thereof is useful as an active ingredient of a therapeutic agent for dysuria.
- the therapeutic agent for dysuria containing the alkylenediamine derivative or a pharmacologically acceptable salt thereof of the present invention can be used by general oral or parenteral administration such as injection or suppository.
- Oral dosage forms include, for example, cat lj, capsules, powders, granules, syrups: ⁇ and the like.
- Parenteral dosage forms include injections, Suppositories and the like can be mentioned. For such preparation, ordinary excipients, disintegrants, binders, lubricants, dyes, diluents and the like are used.
- Excipients include glucose and lactose; disintegrators include starch and carboxymethylcellulose calcium; lubricating agents include magnesium stearate and talc; and binding agents include hydroxypropylcellulose, gelatin, and polyvinylpyrrolidone. Used. In general, the dosage is about 0.1 mg / day for an adult. However, the dose can be increased or decreased depending on the age, symptoms and the like, which is about 1. Omg to 500 mg daily.
- 3400 2500, 1 700, 1 600, 1 590, 1490, 1 340: 1 240, 1 230, 1 1 70, 1 1 20, 1 1 10, 1050, 975, 780, 750, 690, 5 7 0.
- the reaction solution was filtered to remove insolubles, and the solvent was distilled off under reduced pressure.
- 9% aqueous hydrochloric acid (3 OmL) and methanol (3 OmL) were added, and the mixture was heated under reflux for 15 minutes.
- Methanol was distilled off from the reaction solution under reduced pressure, ice water was added to the residue, and the precipitated oil was extracted with dichloromethane. The extract was washed with water and saturated saline, and then dried over anhydrous sodium sulfate.
- the extract was washed with water and brine, and dried over anhydrous sodium sulfate.
- 3400 2925, 1680, 1600, 1450, 1430, 1350, 1310, 1285, 1195, 1 170, 1 140, 985, 750, 745, 650.
- 3400 1710, 1570, 1450, 1340, 1255, 1185, 1130, 1090, 1070, 990, 925, 875, 750, 720, 690, 620, 570.
- the solvent was distilled off from the reaction solution under reduced pressure, 1N hydrochloric acid and ethyl acetate were added to the residue, the aqueous phase was separated, potassium carbonate was added to the aqueous phase to make it basic, and the precipitated oil was extracted with ethyl acetate. .
- the extract was washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was subjected to silica gel column chromatography.
- 3400 2950, 1670, 1590, 1450, 1330, 1300, 1280, 1235, 1190, 1160, 1 155, 1 100, 1060, 980, 910, 810, 790, 730, 690, 550.
- 3400 2925, 2600, 2450, 1690, 1590, 1470, 1440, 1400, 1390, 1335, 1275, 1230, 1 170, 1 135, 1 125, 1 100, 1075, 1050, 1005, 890,
- a saturated aqueous sodium hydrogen carbonate solution was added to the recrystallization mother liquor of [B], and the mixture was extracted with ethyl acetate (1 OOmL). The ethyl acetate layer was washed with saturated saline (20 OmL), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. To the obtained amorphous form (12.0 g, 30.0 mmol) was added methanol (5 OmL) and D- (I) monotartaric acid (4.50 g, 30.0 mmol), and the mixture was heated to 5 CTC. After the solution was made homogeneous, it was left at room temperature overnight.
- the precipitated crystals were recrystallized twice from methanol to give diastereomer monosalt (7.58 g, 69%) having an optical purity of 100% ee as a white powder.
- the product (7.58 g) was added to a saturated aqueous solution of sodium bicarbonate, extracted with ethyl acetate, the ethyl acetate layer was washed with saturated saline, and dried over anhydrous sodium sulfate.
- the desiccant was filtered off, 4N hydrochloric acid gas Z and ethyl acetate (5 mL) were added, and the mixture was left overnight at room temperature.
- a red oil (20 Omg, 41.7%) was obtained from the elution portion of ethyl acetate Zn-hexane (1Z1). 20 Omg of this oil was dissolved in methanol (1 mL), acidified with 3N hydrochloric acid, and then methanol was distilled off under E. Water was added to the residue, and the mixture was allowed to cool to give the title compound (133 mg, 61.0%) as an orange solid.
- Example 30 [3— (4-cyano 4-phenylbiperidino) provir] 1 2 ⁇ —1,2—benzothiazine 1 4 (3 ⁇ ) 1one 1,1 dioxide fumarate Obtained in Example 30 2— (3 1-II, 1,2-Venzothiazine-4 (3 ⁇ ) 1,1-dioxide (485 mg, 1.77 mmol) and 4-cyano 4-phenylbiperidine (330 mg, 77 mmol) In the same manner as in Example 31, the free base of the title compound (41 lmg, 56.7%) and its fumarate (300 mg, 56.9%) were obtained.
- Example 31 Dissolve 4-cyano 4-phenylbiperidine (236 mg, 1.06 mmol) in water (3 mL), make it alkaline with saturated aqueous sodium hydrogen carbonate solution, extract with dichloromethane, and dry the extract with anhydrous sodium sulfate. did. The dried product was placed under reduced pressure and the solvent was distilled off to obtain an oil. As in Example 31, from this oil and the 2- (3-chloro-11-phenylpropyl) -12H-1, 2-benzothiazine-14 (3H) -one 1,1 dioxide obtained in Example 33. This gave the free base of the title compound (16 Omg, 30.2%) and its fumarate (37 mg, 18.8%, orange solid).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/722,112 US5773437A (en) | 1994-03-31 | 1995-03-31 | Alkylenediamine derivatives |
EP95913402A EP0753514A4 (en) | 1994-03-31 | 1995-03-31 | ALKYLENEDIAMINE DERIVATIVES |
KR1019960705433A KR970702267A (ko) | 1994-03-31 | 1995-03-31 | 알킬렌디아민 유도체(alkylenediamine derivative) |
AU20849/95A AU2084995A (en) | 1994-03-31 | 1995-03-31 | Alkylenediamine derivative |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/85831 | 1994-03-31 | ||
JP8583194A JPH07278125A (ja) | 1994-03-31 | 1994-03-31 | アルキレンジアミン誘導体 |
JP10334594 | 1994-04-18 | ||
JP6/103345 | 1994-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995026959A1 true WO1995026959A1 (fr) | 1995-10-12 |
Family
ID=26426838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000632 WO1995026959A1 (fr) | 1994-03-31 | 1995-03-31 | Derive alkylenediamine |
Country Status (6)
Country | Link |
---|---|
US (1) | US5773437A (ja) |
EP (1) | EP0753514A4 (ja) |
KR (1) | KR970702267A (ja) |
CN (1) | CN1148853A (ja) |
AU (1) | AU2084995A (ja) |
WO (1) | WO1995026959A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0831823A4 (en) * | 1995-06-07 | 1998-10-21 | Merck & Co Inc | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
DE60117247D1 (de) * | 2000-03-31 | 2006-04-20 | Purdue Research Foundation West Lafayette | Phosphoramidat-prodrugs |
RU2213744C1 (ru) * | 2002-06-27 | 2003-10-10 | Институт органической химии им. Н.Д. Зелинского РАН | ПРОИЗВОДНЫЕ АНТРА[2,1-d]ИЗОТИАЗОЛ-3,6,11-ТРИОНА |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3712889A (en) * | 1970-05-11 | 1973-01-23 | Recordati Chem Pharm | Oxodihydrobenzothiazine-s-dioxides |
US4272531A (en) * | 1980-06-26 | 1981-06-09 | Smithkline Corporation | 3,3'-Bis-methylene-1,3-benzo-thiazine compounds |
DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
US5274097A (en) * | 1988-04-19 | 1993-12-28 | Bayer Aktiengesellschaft | 1,3-disubstituted pyrrolidines |
JPH02184667A (ja) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | N,n’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤 |
PH31474A (en) * | 1992-07-14 | 1998-11-03 | Nippon Chemiphar Co | N-aminoboalkyl-substituted nitrogen-containing five membered heterocyclic compounds. |
-
1995
- 1995-03-31 AU AU20849/95A patent/AU2084995A/en not_active Abandoned
- 1995-03-31 US US08/722,112 patent/US5773437A/en not_active Expired - Fee Related
- 1995-03-31 EP EP95913402A patent/EP0753514A4/en not_active Withdrawn
- 1995-03-31 KR KR1019960705433A patent/KR970702267A/ko not_active Withdrawn
- 1995-03-31 WO PCT/JP1995/000632 patent/WO1995026959A1/ja not_active Application Discontinuation
- 1995-03-31 CN CN95193184A patent/CN1148853A/zh active Pending
Non-Patent Citations (8)
Title |
---|
ACTA NATURALIA DE L'ATENEO PARMENSE, Vol. 19, (1983), M.R. MINGIARDI, "Composti 1, 2-Benzisotiazolici a Potenziale Attivita beta-Bloccan te", p. 145-151. * |
ARZNEIM. -FORSCH., Vol. 9, (1982), R. BECKER et al., "The Metabolic Fate of Supidimide in the Rat", p. 1101-1111. * |
CHEMICAL ABSTRACTS, Vol. 113, abstract no. 23893 (1990). * |
CHEMICAL ABSTRACTS, Vol. 113, abstract no. 6327 (1990). * |
JOURNAL OF HETEROCYCLIC CHEMISTRY, Vol. 15, No. 16, (1978), JOHN ASHBY et al., "The Transformation of Saccharin into Derivatives of Imidazo (1, 2-b) (1, 2)-Benzisothiazole and Benzo (g) (1, 2, 5) Thia Diazocine", p. 1009-1020. * |
JOURNAL OF MEDICINAL CHEMISTRY, Vol. 16, No. 10, (1973), ENRICO SIANESI et al., "New Benzothiazines. 4. 1H-2, 3-Benzothiazin-4(3H)-one 2, 2-Diotide and 2H-1, 2-Benzothiazin-3(4H)-one 1, 1-Dioxide Nitrogen Derivatives with Central Nervous System Activity", p. 1133-1137. * |
JOURNAL OF ORGANIC CHEMISTRY, Vol. 31, No. 1, (1966), HAROLD ZINNES et al., "1, 2-Benzothiazines. III. The Preparation of 2H-1, 2-Benzothiazin-4(3H)-one 1, 1-Dioxide by the Acid-catalyzed Deacetylation of beta-Diketone", p. 162-165. * |
See also references of EP0753514A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0831823A4 (en) * | 1995-06-07 | 1998-10-21 | Merck & Co Inc | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
US6075038A (en) * | 1995-06-07 | 2000-06-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
US5773437A (en) | 1998-06-30 |
EP0753514A1 (en) | 1997-01-15 |
CN1148853A (zh) | 1997-04-30 |
KR970702267A (ko) | 1997-05-13 |
EP0753514A4 (en) | 1997-08-06 |
AU2084995A (en) | 1995-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4590196A (en) | Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives | |
Inoue et al. | Synthesis of halogen-substituted 1, 5-benzothiazepine derivatives and their vasodilating and hypotensive activities | |
IE50366B1 (en) | Chloro-and alkoxy-substituted-2,4-disminoquinazolines and pharmaceutical compositions containing them | |
JPS62192380A (ja) | インドリジン誘導体、その製造法及びそれを含有する医薬組成物 | |
JPH08506354A (ja) | 5−[2−(4−(ベンゾイソチアゾール−3−イル)−ピペラジン−1−イル)エチル−6−クロロ−1,3−ジヒドロ−インドール−2−オンの製造方法及び製造用中間体 | |
JPS63301861A (ja) | ピペラジニルー複素環式化合物 | |
HU214032B (en) | Process for producing benzoisothiazole and benzoisoxazole-3-carboxamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
EP0433149B1 (fr) | Antagonistes de la sérotonine, leur préparation et les médicaments les contenant | |
TW399051B (en) | A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose | |
JPH0786097B2 (ja) | 新規ヘテロ環置換アルキルアミン、その製造方法および医薬組成物 | |
HU207731B (en) | Process for producing aryl-piperazinyl-alkylene-phenyl-p-heterocyclic compounds, pharmaceutically acceptable acid additional salts and pharmaceutical compositions containing them as active components | |
US5434149A (en) | Thiadiazinones | |
WO1995026959A1 (fr) | Derive alkylenediamine | |
CA2009416A1 (en) | Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them. | |
JPS58128384A (ja) | ベンゾジオキシン化合物、その製造方法、および精神作用障害治療用医薬組成物 | |
JP2883995B2 (ja) | ピペリジン誘導体及びその製造中間体 | |
IL149830A (en) | History of dimethylamino (ethylidene) thioamide, the process for their preparation and their use in the preparation of vascular formation inhibitors | |
KR20010031297A (ko) | 2-치환된 1,2-벤즈이소티아졸 유도체 및 세로토닌 길항제(5-ht1a, 5-ht1b 및 5-ht1d)로서의 그의 용도 | |
US5498720A (en) | Certain triazole compounds and their pharmaceutical uses | |
JP2866277B2 (ja) | アルキレンジアミン誘導体 | |
KR100242480B1 (ko) | 헤테로사이클릭 화합물 및 이를 유효성분으로 하는 강심제 | |
KR840001095B1 (ko) | 2, 4-디아미노퀴나졸린 화합물의 제조 방법 | |
EP0364091B1 (en) | Antipsychotic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)butyl bridged bicyclic imides | |
JPH03178965A (ja) | 心臓血管障害の治療に有用なピリドンニトリル | |
JPH07278125A (ja) | アルキレンジアミン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95193184.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995913402 Country of ref document: EP Ref document number: 08722112 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995913402 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995913402 Country of ref document: EP |